Who Owns Alyftrek?
Alyftrek is owned by Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a publicly traded biopharmaceutical company headquartered in Boston, Massachusetts. Approved by the FDA in December 2024, it is a once-daily triple-combination CFTR modulator that Vertex expects will replace Trikafta for most cystic fibrosis patients over time. The drug generated $837.8 million in its first full year on the market in FY2025.
Parent Company
Founded
2024
Status
Publicly Traded
Headquarters
Alyftrek Timeline
Who Owns Alyftrek?
- Parent Company: Vertex Pharmaceuticals Incorporated
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: NASDAQ: VRTX
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Alyftrek | Vertex Pharmaceuticals Incorporated | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
Alyftrek on AmazonAdvertisement
History of Alyftrek
- Founded: 2024
- Founders: Vertex Pharmaceuticals (internal development)
The program behind Alyftrek began as an effort to solve two problems with Trikafta: its twice-daily dosing and gaps in mutation coverage. Vertex designed a new triple combination, pairing the new corrector vanzacaftor and the potentiator deutivacaftor with tezacaftor, formulated for once-daily dosing.
Phase 3 trials completed in 2024 showed the combination non-inferior to Trikafta on lung function, measured by percent predicted FEV1, and superior on sweat chloride, a biomarker of CFTR activity. It also covered mutations that respond poorly or not at all to Trikafta, widening the treatable population.
The FDA approved Alyftrek on December 20, 2024, for patients six years and older with at least one responsive mutation. European approval followed in 2025. The US launch began in early 2025, making it a first-year product for the fiscal year.
Commercial uptake outpaced some expectations. First-year revenue of $837.8 million made it one of the stronger rare-disease launches on record, and US CF revenue growth of 12% in Q4 2025 was attributed partly to Alyftrek adoption. Vertex states plainly that it expects the majority of CF patients to transition to Alyftrek over time, making the product the company's long-term CF anchor rather than a supplementary option.
Advertisement
About Vertex Pharmaceuticals Incorporated
What does Vertex Pharmaceuticals own?
Vertex owns seven marketed medicines: CF therapies Kalydeco, Orkambi, Symdeko, Trikafta/Kaftrio, and Alyftrek, plus Casgevy (co-owned profit share with CRISPR Therapeutics) and Journavx. Its pipeline includes povetacicept, zimislecel, and inaxaplin. It absorbed Semma, ViaCyte, and Alpine Immune Sciences rather than holding them as separate companies.
Is Vertex publicly traded?
Yes. It trades on NASDAQ under ticker VRTX and is a member of the S&P 500 and NASDAQ-100. Shares have been public since a 1991 IPO.
When was Vertex founded?
Vertex was founded in 1989 in Cambridge, Massachusetts. It moved its headquarters to Boston's Seaport District in 2014.
Who founded Vertex?
Joshua Boger, a former senior scientist at Merck, founded the company with venture capitalist Kevin Kinsella to pursue rational drug design. Reshma Kewalramani is the current president and CEO.
Advertisement
What is Vertex's market position?
Vertex holds an effective monopoly in cystic fibrosis modulators, with medicines used by about 75% of the addressable patient population across 60-plus reimbursed countries. It is among the most valuable biotechnology companies by market capitalization.
Does Vertex own Casgevy?
Vertex co-developed Casgevy with CRISPR Therapeutics and leads commercialization under a profit-sharing agreement, taking 60% of economics. It is not the sole owner of the product.
- Founded: 1989
- Headquarters: Boston, Massachusetts, USA
- Company Type: Publicly Traded
- Stock: NASDAQ: VRTX
- Revenue: $12.0 billion (FY2025)
- Employees: Approximately 6,400
Where Is Alyftrek Made / Based?
- Headquarters: Boston, Massachusetts, USA
- Manufacturing / Operations: United States
Alyftrek Categories & Tags
Alyftrek Recalls & Controversies
Alyftrek carries a safety profile consistent with the CFTR modulator class. Prescribing information includes liver enzyme monitoring requirements shared across the class, and post-launch surveillance is ongoing as expected for a recently approved medicine. No recalls have been issued.
The controversy it inherits is class-level pricing scrutiny. Vertex has not separated Alyftrek's list price dramatically from the franchise norm, keeping it in the same premium bracket that has drawn criticism from patient advocates and payers who note the CF program's partial origin in charity-funded research. Access in lower-income countries remains limited, as it does for all CFTR modulators.
Advertisement
Brands Owned by Vertex Pharmaceuticals Incorporated
Healthcare PharmaceuticalsCasgevy
Owned by Vertex Pharmaceuticals Incorporated
The first approved CRISPR/Cas9 gene-editing therapy, a one-time treatment for sickle cell disease and transfusion-dependent beta thalassemia.
gene-editingcrisprsickle-cell
Healthcare PharmaceuticalsJournavx
Owned by Vertex Pharmaceuticals Incorporated
First-in-class non-opioid acute pain medicine (suzetrigine), a selective NaV1.8 inhibitor approved by the FDA in January 2025.
pain-managementnon-opioidnav1-8
Healthcare PharmaceuticalsTrikafta
Owned by Vertex Pharmaceuticals Incorporated
Triple-combination CFTR modulator (elexacaftor/tezacaftor/ivacaftor) treating the underlying cause of cystic fibrosis in roughly 90% of patients.
cystic-fibrosiscftr-modulatorrare-disease
Alyftrek Ownership: Pros & Cons
Advantages
- +Sole-source status: no competitor makes a CFTR modulator
- +Once-daily dosing and broader mutation coverage improve on the incumbent standard
- +Patent composition extends franchise exclusivity beyond Trikafta's window
- +$837.8 million first-year revenue shows payer and prescriber acceptance
- +Shared supply chain with the existing CF franchise lowers launch cost
Considerations
- -Growth depends on cannibalizing Trikafta rather than winning new markets
- -Class-typical liver monitoring burden remains a prescribing friction
- -Premium pricing continues to attract payer and political criticism
- -Rare-disease market size caps the long-term revenue ceiling
- -Access gaps in poorer markets leave reputational exposure
Advertisement
Frequently Asked Questions About Alyftrek
Sources & Further Reading
Advertisement
Competitors to Alyftrek
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals | USA | 2019 | Mass market | Global | All-ages | |
| Vertex Pharmaceuticals | USA | 2025 | Mass market | United states | All-ages |
Learn More About Competitors
Healthcare PharmaceuticalsTrikafta
Owned by Vertex Pharmaceuticals Incorporated
Triple-combination CFTR modulator (elexacaftor/tezacaftor/ivacaftor) treating the underlying cause of cystic fibrosis in roughly 90% of patients.
cystic-fibrosiscftr-modulatorrare-disease
Healthcare PharmaceuticalsJournavx
Owned by Vertex Pharmaceuticals Incorporated
First-in-class non-opioid acute pain medicine (suzetrigine), a selective NaV1.8 inhibitor approved by the FDA in January 2025.
pain-managementnon-opioidnav1-8
Competitive Analysis
Market Positioning: Alyftrek competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Alyftrek
Looking for brands with different ownership structures? These similar brands are not owned by Vertex Pharmaceuticals Incorporated, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsAvaility
Owned by Availity
The largest real-time health information network in the US, owned by a consortium of major health insurers and Novo Holdings.
healthcare-technologyclearinghouseclaims-processing
Privately Owned
Availity is privately owned, unlike Alyftrek which is under a publicly traded parent company.
Healthcare PharmaceuticalsBand-Aid
Owned by Kenvue
American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid is the leading adhesive bandage brand in the United States and is sold in more than 100 countries.
wound-careadhesive-bandagefirst-aid
Privately Owned
Band-Aid is privately owned, unlike Alyftrek which is under a publicly traded parent company.
Healthcare PharmaceuticalsBenadryl
Owned by Kenvue
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
antihistamineallergy-reliefcold-medicine
Privately Owned
Benadryl is privately owned, unlike Alyftrek which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoots
Owned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
pharmacyhealth-beautyuk-retail
Privately Owned
Boots is privately owned, unlike Alyftrek which is under a publicly traded parent company.
Healthcare PharmaceuticalsDuane Reade
Owned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
pharmacydrugstorenew-york
Privately Owned
Duane Reade is privately owned, unlike Alyftrek which is under a publicly traded parent company.
Healthcare PharmaceuticalsMD Clarity
Owned by MD Clarity
Seattle healthcare SaaS platform for patient cost estimates, payer contract management, and underpayment detection.
healthcare-technologyrevenue-cyclecontract-management
Privately Owned
MD Clarity is privately owned, unlike Alyftrek which is under a publicly traded parent company.
Vertex Pharmaceuticals Incorporated Stock Information
Advertisement
Jobs at Vertex Pharmaceuticals Incorporated
Latest News About Alyftrek
Advertisement
Related Articles About Alyftrek
View more articles
News & Updates
Monthly IPO Roundup: November 2026 -- October's Biggest Listings
October 2026 IPOs: Jio Platforms set India's all-time record at $3.2B and surged 27%, GCash owner Mynt raised a Philippine-record P60.9B, Anthropic filed publicly for a possible mid-November debut, and U.S. listings were a biotech grab bag. Full recap.
Who Brands StaffNov 6, 2026
Ipo RoundupIpoStock Market
News & Updates
Monthly M&A Roundup: October 2026 Brand Ownership Changes
October 2026's biggest deals: Paramount Skydance closed its $110B Warner Bros. Discovery takeover, Salesforce signed Braze for $5.66B, Proofpoint bought Varonis for $6.3B, the Weston family agreed to buy Boots for $8.9B, and Viatris added Pacira for $1.65B. Full breakdown.
Who Brands StaffNov 6, 2026
M And A RoundupAcquisitionsNews
Rivalry
Duracell vs Energizer: The Battery Brand Rivalry
Duracell is Berkshire Hathaway-owned (25-30% US share). Energizer is publicly traded (NYSE: ENR) with Rayovac. Together they control ~85% of branded US batteries, but Amazon Basics has 27.1% online. Explore our database.
Who Brands StaffOct 23, 2026
DuracellEnergizerRivalry
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Brandspecialty-pharmacy
Accredo
Specialty pharmacy founded in 1996 in Memphis, serving patients with complex and rare conditions as the specialty pharmacy of Evernorth within The Cigna Group.
Brand in Healthcare & Pharmaceuticals
rare-diseaseevernorth